Search filters

Filters
Clear All

Phase

  • 4
  • 1
  • 3
  • 1
  • 9
  • 19
  • 16
  • 19

Found 19 multiple myeloma trials

A listing of multiple myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Tissue Collection for Multiple Myeloma Research
18-99 years
All genders
Interventional
The primary purpose of this research study is to obtain specimens (blood, bone marrow, and other tissues) for research about multiple myeloma and related diseases.
99 years and younger
All genders
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
99 years and younger
All genders
Phase 2
Please refer to Protocol Section 4 Please refer to Protocol Section 4 Please refer to Protocol Section 4
99 years and younger
All genders
Phase 2
The research study is being conducted to see if combining an investigational drug, called belantamab mafodotin, with standard-of-care autologous stem cell transplant and maintenance therapy in patients with myeloma can help reduce the amount of myeloma cells that can be detected in patients after transplant. We will also study if …
99 years and younger
All genders
he purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
18-99 years
All genders
Interventional
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
99 years and younger
All genders
We are doing this study to see if CAR T-cell therapy (bb2121) and maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back.
99 years and younger
All genders
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. We would like to rely on WCG as the IRB of record for this study.
18-99 years
All genders
Interventional
Participants invited to participate in a research study must have diagnosis of multiple myeloma and have been previously treated with the study drug, cilta-cel. The purpose of this research is to monitor the health status of subjects who were previously enrolled in cilta-cel.
1 - 10 of 19